Abstract：Conventional treatment of type 2 diabetes is to use multiple oral anti-hyperglycemic drugs and/or insulin based on the control of diet and physical activity. We emphasize the efficacy and safety of the new drug—Glucagon-like peptide-1 analogue (Liraglutide) in clinical trials of treating patients with type 2 diabetes. The results of large scale of LEAD series study, clinical study in Asian especial y Chinese patients approve liraglutide’s multiple beneficial. Liraglutide decreases blood glucose in glucose-dependent manner, protectsβcel function, decreases body weight as wel as reduces systolic blood pressure. Besides, the rates of hypoglycemic and other side ef ects are low, thus providing a better way to treat type 2 diabetes.
2013, Vol. 11 
